2026-04-13T01:30:06Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2222762026-04-07T22:03:21Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc García Castillo, María Clara author Sierra Mencía, Álvaro author Caronna, Edoardo author Toledo Alfocea, Daniel author Jaimes, Alex author Urtiaga, Saray author Casas Limón, Javier author Muñoz Vendrell, Albert author Santos Lasaosa, Sonia author García Martín, Valvanuz author Martín Ávila, Guillermo author Polanco, Marcos author Villar Martínez, María Dolores author Trevino Peinado, Cristina author Rubio Flores, Laura author Sánchez Soblechero, Antonio author Portocarrero Sánchez, Leonardo author Luque Buzo, Elisa author Lozano Ros, Alberto author Gago Veiga, Ana Beatriz author Díaz de Terán, Javier author Recio García, Andrea author Canales Rodríguez, Javiera author Gómez García, Andrea author González Salaices, Marta author Campoy Diaz, Sergio author Mínguez Olaondo, Ane author Maniataki, Stefania author González Quintanilla, Vicente author Porta Etessam, Jesús author Cuadrado, María Luz author Guerrero Peral, Ángel Luis author Pozo Rosich, Patricia author Rodríguez Vico, Jaime author Huerta Villanueva, Mariano author Pascual, Julio (Pascual Santos) author Goadsby, Peter J. author González Martínez, Alicia author 2025-07-16T09:06:41Z 2025-07-16T09:06:41Z 2025-06-03 2025-07-14T10:31:08Z Background Preclinical evidence supports the immunoregulatory role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology. The increasing use of anti-CGRP therapies in patients with migraine and other comorbidities raises the question whether the potential use of anti-CGRP monoclonal antibodies (CGRP-mAbs) therapies in combination with other immunological therapies is effective and safe. Methods This multicenter study included patients with migraine receiving CGRP-mAbs combined with immunosuppressive and immunomodulatory treatments. Clinical and demographic data, treatment history, laboratory markers and treatment-emergent adverse events (TEAEs) were analyzed. Effectiveness outcomes included the change in monthly migraine days (MMD) and monthly headache days (MHD) at 3, 6, 9 and 12 months, alongside the > 50% response rate. Moreover, autoimmune disease progression was also evaluated. We explored differences between patients with and without autoimmune disease activation. Results Among 89 patients, there were 80 (90%) females with a mean age of 50 years (SD: 11), who had a high prevalence of psychiatric comorbidities (anxiety 44%, depression 49%) and medication overuse (68%). Patients receiving immunological treatments experienced significant reductions in MMD and MHD, with MMD decreasing from 16 (SD: 7) at baseline to 9 (SD: 8) at 6 months, and MHD dropping from 23 (SD: 8) to 17 (SD: 11). A 50% response in MMD was achieved by 46% at 6 months. TEAEs were reported in 28%, most commonly constipation (16%) and dizziness (9%). Conclusions CGRP-mAbs therapies combined with immunological treatments appear effective and safe in patients with autoimmune diseases. Larger prospective studies are necessary to confirm these findings and optimize management strategies. Migranya Immunofarmacologia Migraine Immunopharmacology Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies